Matthew Durdy is the Chief Business Officer of the Cell Therapy Catapult. He leads the group which is responsible for sourcing, funding, negotiating and marketing the portfolio of activities of the company, as well as developing business and reimbursement strategies. He is one of the original Executive Team responsible for designing and founding the Cell Therapy Catapult.
During the previous 12 years he gained broad experience in the biotechnology industry leading SMEs, raising finance and commercialising diagnostics, medical devices, and therapeutics for regulated use in the EU. During this period he was also an expert advisor to the World Health Organisation on medical innovation strategy.
Prior to this, Matthew was a Director at the venture capital firm CDC, where he was responsible for due diligence and new investment in their $3.5bn international portfolio. He completed his training in corporate finance and international investment banking at Bank of America Hoare Govett and Prudential Bache, in New York and London.
He has an MA in Pure and Applied Biology from Christ Church, University of Oxford, and an MBA from the University of Chicago Booth School of Business. He is a fellow of the Chartered Institute of Securities and Investment and assists in teaching new venture strategy at Chicago Booth.